A SUSTAINED -RELEASE COMPOSITION CONTAINING A MELANOCORTIN RECEPTOR LIGAND AS THE ACTIVE INGREDIENT

The present invention relates to a sustained-release drug composition consisting essentially of microparticies of a peptide as the active substance and a biocompatible water-soluble polymer, in particular peptide as meianocortin receptor ligand. The present invention relates also to an injection for...

Full description

Saved in:
Bibliographic Details
Main Authors Béatrice HACHER, Didier NOURRISSON, Marie-Madeleine BARONNET, Jeremiah HARNETT, Nathalie MONDOLY, Joël RICHARD, Faïza LAREDJ, Laurent BERTOCCHI
Format Patent
LanguageEnglish
Spanish
Published 29.08.2016
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to a sustained-release drug composition consisting essentially of microparticies of a peptide as the active substance and a biocompatible water-soluble polymer, in particular peptide as meianocortin receptor ligand. The present invention relates also to an injection formulation comprising the sustained-release drug composition suspended in an injection medium. La presente invención se refiere a una composición de fármaco de liberación sostenida que consiste esencialmente de microparticulas de un péptido como la sustancia activa y un polímero soluble en agua biocompatible, en particular péptido como ligando receptor de melanocortina. La presente invención se relaciona también a una formulación de inyección que comprende la composición de fármaco de liberación sostenida suspendida en un medio de inyección.
Bibliography:Application Number: MX20130013691